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Introduction
Somatostatin, especially its long acting analogues like
octreotide and lanreotide play a very important role in
diagnosis and treatment of patients with neuroen-
docrine tumors (NETs). Their effectiveness depends
on the expression of specific somatostatin receptors
(SSTR) on the target cells. Five subtypes of the SST
receptor have been identified, i.e. SSTR 1-5 with two
splicing variants (2A and 2B) of the type 2 receptor
[for review see: 1]. Lately, the novel two variants of
SSTR 5 (SSTR 5B and SSTR 5C) has been identified
[2]. All of the subtypes belong to a family of 7 trans-
membrane domains linked with the G protein and are
encoded by 5 genes present on separate chromosomes
[3,4]. To make appriopriate diagnosis different tech-
niques in vivo or ex vivo are being currently applied to
detect SST receptors in human tumors. Octreoscan,
receptor scintigraphy using indium labeled SST
analogs: 111 In-pentetreotide {[111 In-DTPA]
octreotide} [5-8], 111 In-DOTA-lanreotide [9] or tech-
netium labeled [99mTc-EDDA/HYNIC-Tate] octreo-
tate [10,11] have been proved most useful in vivo (Fig.
1). These methods allow to determine in vivo the tumor
localization and size with good precision, however
their effectiveness depends on the presence of subtype
2 SSTR in the tumor. The negative results obtained
with octreoscan in pheochromocytoma or neuroen-
docrine tumors where the presence of SST receptors in
the investigated tumors was demonstrated using the
immunohistochemical method have been published
[12,13]. There could be a considerable variation in
SSTR expression between the different tumors types
but also among tumors of the same type [4,14]. The
diversity and coexistence of several somatostatin
receptor subtypes in the same tumor unables an
unequivocal prediction which somatostatin analog will
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be effective in its treatment. The immunohistochemi-
cal (IHC) technique performed on paraffin embedded
tissue specimens obtained from surgically removed
tumors which are routinely used for histopathological
examinations seems the best ex vivo in vitro method
in detecting expression of SST receptors [15,16]. It
searches the expression of receptors at the receptor
protein level and gives us insight into receptor's cel-
lular localization. Currently applied methods of
molecular biology (PCR, RT-PCR, in situ hybridiza-
tion -ISH, Northern-blotting) detect only the receptor
mRNA, while giving no insight into receptor local-
ization. The IHC method should be considered equal-
ly effective as diagnostic molecular biology methods
or in vivo radiodiagnostic imaging. This method can
be considered as having a high efficacy. In our previ-
ous studies we have investigated the immunohisto-
chemical detection of SSTR expression in pituitary
adenomas [17,18], adrenal gland tumors [19], thyroid
tumors [20] using antibodies specific for a given
receptor subtypes.
The aim of this study was to assess the presence of
all the 5 subtypes of SSTR 1-5 (including 2A and 2B
SSTR isoforms) in surgically treated human neuroen-
docrine tumors to establish which receptor subtype is
the dominant form of somatostatin receptor in particu-
lar tumor and thus to predict which somatostatin
analogs should be effective in NETs treatment.
Materials and methods
Tissue samples. Eighteen samples of neuroendocrine tumors (sur-
gically excised tumors or biopsies) from 13 patients (11 women
and 2 men, aged between 32-70 years, mean age 52.9) archivized
in the Department of Neuroendocrinology were assessed. The
material included 7 biopsy specimens of carcinoid metastases to
the liver, 5 lung carcinoids, 1 intestinal carcinoid (contained pri-
mary focus and 3 metastases), 1 pancreatic neuroendocrine tumor
and 1 thymic neuroendocrine tumor with ectopic secretion of
ACTH , causing Cushing's syndrome. 
Immunohistochemistry. For somatostatin receptor subtypes
determination, 10% formalin or Bouin-Hollande fixed, dehydrated
and paraffin embedded 4-5 μm sections were immunostained using
commercially available rabbit polyclonal antisera raised against
carboxyl-terminal fragments of specific human somatostatin recep-
tor subtypes (GRAMSCH Laboratories, Schwabhausen, Ger-
many): SSTR 1 (named SS-840 antibody, corresponding to amino
acid sequence 377-391 of the receptor's peptide chain), SSTR 2A
(SS-800, specific for 355-369 sequence), SSTR 2B (SS-860, spe-
cific for 342-356 sequence), SSTR 3 (SS-850, specific for 381-395
sequence), SSTR 4 (SS-880, specific for 374-388 sequence) and
SSTR 5 (SS-890, specific for 350-364 sequence). The immunohis-
tochemical procedures were performed as previously described
[21]. At first sections were dewaxed in xylene and rehydrated in
ethanol. The antigen retrieval procedure performed prior to pri-
mary antibody incubation consist on microwave treatment in 
0.01 M citric acid buffer (pH 6.0) two times for 5 min at 720 W and
one time in 420 W. To quench endogenous peroxidase activity sec-
tions were incubated in methanol containing 1.5% H2O2 for 30 min
at room temperature. The non-specific binding was blocked by
preincubation with 3% normal goat serum for 30 min at room tem-
perature. The working dilution of antibodies was 1: 1000 (diluted
in 0.05 M TRIS buffer, pH 7.6 containing 2% goat serum). Fol-
lowing overnight incubation in 4°C in humidified chamber with
primary antibodies, the tissues were treated with anti-rabbit IgG
biotinylated goat antibody (1:800, DAKO, Denmark) and strepta-
vidin complex (Strept ABC/HRP, DAKO, Denmark). The
immunoreaction was visualized with 3.3'-diaminobenzidine (DAB,
DAKO, Denmark) solution. For negative control the primary anti-
body was omitted and the normal goat serum was used. At least six
sections per one tumor were examined. Because immunopositive
tumors differed rather by intensity of staining and not by percent-
age of positive cells (which was usually near to 100%), the exam-
ination concerned semiquantitative evaluation of the staining
intensity and not of positive cells counts. The evaluation was done
by two independent observers.
The immunoreactive intensity for specific receptor proteins
was scored semiquantitatively using a descriptive scale as follows:
strong staining (+++), moderate staining (++), weak staining (+)
and trace staining (+/-). Only strong (+++) or moderate (++) stain-
ing was considered as positive of the given subtype of SSTR in the
further descriptions. Subcellular distribution of SSTR subtypes –
membranous or cytoplasmic was also determined. 
Ethical issues. This project received the approval of the Ethics
Committee of Medical University of £ódŸ, no. RNN/97/06/KE.
Results
The expression of somatostatin receptor subtypes
SSTR 1-5 was very differentiated both between the
different tumors types and among tumors of the same
type (carcinoids). Multiple SSTR subtypes were found
to coexist in almost all of them. Strong and moderate
positive immunostaining of SSTR 1 was observed in
11/17 samples (64.7%). In 6/17 the intensity of reac-
tion was variable (weak, weak to moderate, or even
weak to strong). This subtype of SSTR was the domi-
nant form among all of neuroendocrine tumors inves-
tigated (Tab.1). Somewhat lower score: 10/17 (58.8%)
cases was shown for SSTR 5. The scores 7/18 (38.9%)
and 8/17 (47.1%) tumors were found in SSTR 2A and
SSTR 3 respectively. Only 2 out of 15 (13.3%) sam-
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Fig. 1. SRS – high density of somatostatin receptors in carcinoid
metastasis to the liver. Octreoscan – [99mTc-EDDA/HYNIC-Tate]
octreotate – Green -yellow-orange colours of metastasis in the
liver.
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ples demonstrated SSTR 2B immunopositivity of this
intensity. None of the tumor representing SSTR 4 pos-
itive reaction was found. Female patient with carcinoid
metastasis to the liver exhibited definitively strong
intensity of staining of four subtypes (SSTR 1, 2A, 2B,
3) with trace reaction for SSTR 5. It is worth of inter-
est that in several samples one could observed the
extremely variable score from negative to strong or
from weak to strong reaction in cell clusters in partic-
ular tumors. Summarized pattern of SSTR expression
in the investigated neuroendocrine tumors was: SSTR
1> SSTR 5> SSTR 3> SSTR 2A> SSTR 2B. The
receptors immunopositivity was localized mainly in
the area of cells cytoplasm with a few specimens
showing only membranous or mixed: membranous –
cytoplasmic localization. 
In the thymic neuroendocrine tumor only 30% of
cells expressed SSTR 3 and SSTR 5 at the moderate
intensity, remaining subtypes were at the weak level or
negative. The strong immunoreaction in the vascular
endothelium was also visible (Fig. 2). Pancreatic neu-
roendocrine cancer revealed SSTR 1 immunopositivi-
ty at the moderate to strong level. The other subtypes
were weak or negative although we observed extreme
score from negative to strong in some cell clusters
(Fig. 3). In our series of neuroendocrine tumors the
carcinoids and carcinoid metastases were the main
group 16 all of the NETs samples. The same pattern of
SSTR expression as in the all group was observed:
SSTR 1> SSTR 5> SSTR 3>SSTR 2A> SSTR 2B.
Discussion
Results of the present study demonstrate that somato-
statin receptors are expressed in neuroendocrine
tumors in a varied manner which is specific in each
case. Multiple SSTR subtypes were found to coexist in
each case of the investigated tumor with mixed distri-
bution and various intensity. Our results did not con-
firm the earlier studies of other investigators where the
SSTR 2 predominance is found in >80% of endocrine
pancreatic and digestive tract tumors [22,23]. Among
the 20 carcinoid tumors investigated by Kimura et al.
[24] all except 2 cases (90%) showed moderate to
strong immunoreactivity of SSTR 2A distributed
mainly on the cell membrane and less intensively in
the cytoplasm of the tumor cells. Carcinoid tumors
examined by de Herder et al. [4] also showed the pre-
dominant expression of SSTR 2. Nasir et al. [25] have
examined by immunohistochemistry 11 hepatic metas-
tases of small intestinal carcinoids and have found
SSTR 1 expression in 63%, while SSTR 2 was
expressed in 81%, SSTR 3 in 72%, SSTR 4 in 54%
and SSTR 5 in 91%. In the large majority of cases
studied, the reaction was diffused in the cell cytoplasm
although membranous localization was also noted. The
authors explain this fact that their patients were on the
octreotide treatment at the time of surgery. It is known
that this somatostatin analog causes the receptor inter-
nalization and in consequence increases the SSTR-
positivity in cells cytoplasm. In our group of patients
we did not have any precise information about earlier
therapy before surgery or biopsy, but certainly some of
them were treated with octreotide. In the study of
Kulaksiz et al. [26] immunohistochemical estimation
of SSTR in carcinoids, revealed 37% of SSTR 1, 86%
of SSTR 2A, 71% of SSTR 3 and 83% of SSTR 5
using the same specific antibodies as we did.
Immunoreactivity for the receptor subtypes 1, 3 and 5
was mainly localized in the cytoplasm while SSTR 2A
was found exclusively on the cell membrane of all
tumors were this type of receptor was expressed.
These authors suggest, that the rapid targeting and
integration of this receptor subtype into the cell mem-
brane is responsible for inability of its detection in the
cytoplasm. In our study, the lower score of positive
SSTR expression is due to selection only strong or
moderate staining as positive of the given subtype of
SSTR in the descriptions. We used the antibodies of
same kind and source and SSTR 2A (code SS-800)
was find in 38.9 %, both in cytoplasm and cell mem-
brane (Fig. 3, 4). Overall, SSTR 2A was more frequent
than SSTR 2B. SSTR 1, 3, 5 also were characterized
by a mixed distribution (Fig. 5, 6). Consequently, in
present study, we could not consider these antibodies
(SS-840, SS-850, SS-890 respectively) as recognizing
preferentially internalized receptors as Kulaksiz's
group claims [26]. SSTR 2A antibody in our samples
not only detected the integral membrane form of the
receptor, but also the receptor protein located in the
cytoplasm. Papotti et al. [27] reported their results of
immunohistochemical studies in 15 gastrointestinal
Table 1. Summarized results concerning expression of somatostatin receptor subtypes in neuroendocrine tumors, determined by immuno-
histochemistry method (IHC).
The immunoreactive intensity for specific receptor proteins was scored semiquantitatively using a descriptive scale as follows: strong staining (+++), 
moderate staining (++), weak staining (+) and trace staining (+/-). Only strong (+++) and moderate (++) staining was considered as positive of the given
subtype of SSTR.
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endocrine tumors, in which SSTR 2 immunoreactivity
with the same antibody used by us (SS-800 from
Gramsch Lab.) was found in 12/15 (80%) of tumors
with cell membrane localization, SSTR 3 in 9/15
(60%) (the same antibody, too, from Gramsch Lab),
SSTR 5 in 12/15 (80%) with cell membrane and cyto-
plasmic reactivities. Either cytoplasmic or membra-
nous distribution of SSTR 2A was also reported by
other authors using the same kind of antibodies in
fixed, paraffin embedded samples (SS-840, SS-800,
SS-850, SS-890) [18-20,28-30] . The studies of Jais et
al. [31] using the molecular biology methods (PCR)
showed the following expression of SSTR – mRNAs
in 6 carcinoids investigated among 38 gastroen-
Fig. 2. Negative immunostaining of SSTR 2A in the thymic neu-
roendocrine tumor. Strong immunoreaction in the vascular
endothelium (original magnification ×200). Fig. 3. Membranous
localization of SSTR 2A (pancreatic neuroendocrine cancer),
(original magnification ×200). Fig. 4. Strong to moderate
immunostaining of SSTR 2A in intestinal carcinoid metastasis
with mixed membranous and cytoplasmic localization, (original
magnification ×400). Fig. 5. Immunohistochemical staining of
SSTR 1 in lung carcinoid. Moderate to strong intensity of staining
with cytoplasmic and membranous distribution, (original magnifi-
cation ×400). Fig. 6. Cytoplasmic immunostaining of SSTR 5 in
intestinal carcinoid metastasis, (original magnification ×400).
teropancreatic tumors (GEP): 5/6 (83%) of SSTR 1,
equally: 6/6 ( 100%) of SSTR 2, SSTR 4 and SSTR 5,
1/6 (17%) of SSTR 3. However, Reubi et al. [32] by in
situ hybridization histochemistry detected SSTR 
1 mRNA in 5/10 (50%), SSTR 2 mRNA in 7/10 (70%)
and SSTR 3 mRNA in only 2/10 (20%) of carcinoids.
The results achieved by another group of researches
[33] also reported on the different distribution of
somatostatin receptor subtypes in 9 carcinoids tested
by RT-PCR method: 44% of SSTR 1 mRNA, 67% of
SSTR 2 mRNA, 33% of SSTR 4 mRNA and 56% of
SSTR 5 mRNA. They did not detect the SSTR 
3 mRNA in any of carcinoid cases tested. In our find-
ings in turn there was no immunopositivity for subtype
4 of SST receptor in none of tested samples. Only
Papotti's group [27] reported a poorly expressed SSTR
4 in pancreatic endocrine tumors and in 15.4% (2/13)
of gastrointestinal endocrine tumors
Thus the divergence in results is evident and SSTR
1-5 expression pattern depends on the method of
investigation used. The molecular biology method
(mainly PCR ) is now more often used to investigate
receptor expression. PCR gives results at the level of
mRNA. However, even despite of gene expression it
could occurs the posttranslational modification of
SSTR without protein synthesis. Thus, mRNA detec-
tion alone is not sufficient to confirm the presence of
receptor protein which is the molecular target for
somatostatin and its analogs [16,34]. In this method we
could not obtain also the data concerning localization
of receptor at the cellular level and thus to presume the
receptor activity. Some authors concern as
immunopositive and active only membrane located
SSTR 2 but for SSTR 3 and SSTR 5 only its cytoplas-
mic localization [35,36] in neuroendocrine tumors.
Conclusions 
To summarize, somatostatin receptors are expressed in
neuroendocrine tumors in a varied manner which is
specific in each case. The summarized pattern of SSTR
expression in the investigated neuroendocrine tumors
in our material was: SSTR 1> SSTR 5> SSTR 3>
SSTR 2A> SSTR 2B. The observed pattern suggests
that apart from SSTR 2 and SSTR 5- preferring
octreotide and lanreotide, newly synthesized multili-
gand analogs such as SOM 230 -pasireotide, KE 108
or SSTR 1 and SSTR 5 selective analogs could be
effective in NETs treatment. The receptors were dis-
tributed mainly in the area of cells cytoplasm with a
few specimens showing only membranous or mixed,
membranous – cytoplasmic localization.
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